Dr. Meteb Alfoheidi


Present Title and AffiliationMedical Oncology Consultant – Breast Cancer Sub-specialty

Princess Noorah Oncology Center – National Guard Health Affairs, Jeddah

Assistant Professor &

Medical Oncology Block Cordinator

King Saud Bin Abdulaziz University for Health and Science – Jeddah

Western Oncology Group Director

Saudi Oncology Society

Education2009-2010Breast Cancer Fellowship – University of British Columbia, Canada. 2007-2009Medical Oncology Residency Program (PGY 4-5) – University of British Columbia, Canada 2004-2007Internal Medicine Residency Program (PGY 1-3) – University of Toronto, Canada2000Bachelor Degree of Medicine and Surgery – King Faisal University, KSAExperienceMEDICAL ONCOLOGY2010 – PresentMedical Oncology, Breast Cancer Consultant, National Guard Health Affairs.2009 – 2010Breast Cancer Staff, British Columbia Cancer Centre, Canada.2007 – 2009Medical Oncology Resident, British Columbia Cancer Centre.2004 – 2007Internal Medicine Resident, University of Toronto, Canada.

ADULT MEDICINE2001 – 2004Resident, National Guard Health Affairs, Jeddah.



Friday 3-5-2024 Day 1

Oncologists/pathologists dialogue TILS and descalation of systemic therapy in early breast cancer?


Friday 3-5-2024 Day 1

Transition from hormonal-based to chemotherapy in metastatic BC??

  • Patients with early progression on CDK4-6 inhibitors: What is next??
  • When to start ADCs/olaparib in patients who had visceral crisis?? Can be upfront??
  • Any role of hormonal monotherapy after CDK4-6 inhibitors??
  • Biomarkers to guide subsequent therapies
  • Can we use one ADC after previous ADC??

Moderator:  Dr. Ahmed Alfaraj